Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in? (Q36913018)

17 August 2017

1 reference

title

Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in? (English)

1 reference

17 August 2017

1 reference

cardiovascular disease

1 reference

2

Wolfgang Koenig

1 reference

17 August 2017

Natalie Khuseyinova

1

1 reference

17 August 2017

1 January 2007

1 reference

Molecular Diagnosis and Therapy

17 August 2017

1 reference

17 August 2017

11

1 reference

17 August 2017

4

1 reference

17 August 2017

203-217

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256242

17 August 2017

0 references

cites work

Platelet-activating factor acetylhydrolases

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Platelet-activating factor acetylhydrolase (PAF-AH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Anti-inflammatory properties of a platelet-activating factor acetylhydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Platelet-activating factor acetylhydrolases in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Effect of 17 beta-estradiol on secretion of platelet-activating factor acetylhydrolase by HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infar

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Genetics and heritability of coronary artery disease and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A(2) : review of its role as a marker and a potential participant in coronary endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Biochemical indicators of cardiac and renal function in a healthy elderly population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Use and misuse of the receiver operating characteristic curve in risk prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

PLAC test for identification of individuals at increased risk for coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

The effect of statin therapy on lipoprotein associated phospholipase A2 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Association between Lp-PLA2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256242

Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study

21 January 2018

1 reference

12 December 2020

Plasma platelet-activating factor acetylhydrolase activity is not associated with premature coronary atherosclerosis

1 reference

12 December 2020

Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications.

1 reference

12 December 2020

Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology

1 reference

12 December 2020

Estrogen replacement therapy decreases platelet-activating factor-acetylhydrolase activity in post-menopausal women

1 reference

12 December 2020

An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Lipoprotein-Associated Phospholipase A 2 , Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death

1 reference

12 December 2020

Platelet-activating factor acetylhydrolase in plasma lipoproteins of healthy men and women

1 reference

12 December 2020

Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review

1 reference

12 December 2020

1 reference

12 December 2020

Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults.

1 reference

12 December 2020

The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia

1 reference

12 December 2020

Biological variability of 26 clinical chemistry analytes in elderly people

1 reference

12 December 2020

High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients

1 reference

12 December 2020

Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis

1 reference

12 December 2020

Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease

1 reference

12 December 2020

Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 and coronary calcification. The Rotterdam Coronary Calcification Study

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II).

1 reference

12 December 2020

Molecular Basis of the Interaction between Plasma Platelet-activating Factor Acetylhydrolase and Low Density Lipoprotein

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community

1 reference

12 December 2020

Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma

1 reference

12 December 2020

Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256242

1 reference

17 August 2017

1 reference

PubMed ID

17705575